Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Harnessing the immune system to combat disease has revolutionized medical treatment. Monoclonal antibodies (mAbs), in particular, have emerged as important immunotherapeutic agents with clinical relevance in treating a wide range of diseases, including allergies, autoimmune diseases, neurodegenerative disorders, cancer, and infectious diseases. These mAbs are developed from naturally occurring antibodies and target specific epitopes of single molecules, minimizing off-target effects. Antibodies can also be designed to target particular pathogens or modulate immune function by activating or suppressing certain pathways. Despite their benefit for patients, the production and administration of monoclonal antibody therapeutics are laborious, costly, and time-consuming. Administration often requires inpatient stays and repeated dosing to maintain therapeutic levels, limiting their use in underserved populations and developing countries. Researchers are developing alternate methods to deliver monoclonal antibodies, including synthetic nucleic acid-based delivery, to overcome these limitations. These methods allow for in vivo production of monoclonal antibodies, which would significantly reduce costs and simplify administration logistics. This review explores new methods for monoclonal antibody delivery, including synthetic nucleic acids, and their potential to increase the accessibility and utility of life-saving treatments for several diseases.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
- Date Crossref
- 06/07/2023
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Harvard University Massachusetts General Hospital pays non établi dans la noticeUniversité ou école supérieure
-
Massachusetts General Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Pennsylvania pays non établi dans la noticeUniversité ou école supérieure
-
The Wistar Institute pays non établi dans la noticeStructure de recherche
-
Inc. GeneOne Life Science pays non établi dans la noticeEntreprise
-
Perelman School of Medicine Department of Microbiology pays non établi dans la noticeUniversité ou école supérieure
Massachusetts General Hospital — Harvard University, Massachusetts General Hospital et University of Pennsylvania, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.